ThaiPR.NET https://www.thaipr.net/location/florence-italy-and-boston Press Release Distribution Center of Thailand Fri, 17 Apr 2026 17:23:52 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant]]> https://www.thaipr.net/en/health_en/3205655 Thu, 23 Jun 2022 15:14:59 +0700 health_en https://www.thaipr.net/en/health_en/3205655 Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-month FDA review Positive EMERALD study data previously announced on October 20, 2021 First, and currently only, investigational oral SERD with positive topline results Additional data presented at SABCS (December 2021) and ASCO (June 2022) Plan […]

The post Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting]]> https://www.thaipr.net/en/health_en/3199107 Wed, 08 Jun 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3199107 Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the […]

The post Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology]]> https://www.thaipr.net/en/health_en/3192994 Mon, 23 May 2022 14:39:44 +0700 health_en https://www.thaipr.net/en/health_en/3192994 Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population Data demonstrated elacestrant significantly reduced the risk of disease progression or […]

The post Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology appeared first on ThaiPR.NET.

]]> <![CDATA[Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021]]> https://www.thaipr.net/en/health_en/3132514 Mon, 13 Dec 2021 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3132514 – Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population – In the overall population, elacestrant reduced risk of progression or death by 30% vs. SoC – In the mESR1 population, […]

The post Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021 appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer]]> https://www.thaipr.net/en/health_en/3112567 Thu, 21 Oct 2021 16:15:48 +0700 health_en https://www.thaipr.net/en/health_en/3112567 – Study met both primary endpoints in patients with ER+/HER2- advanced or mBC – Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC – Elacestrant extended PFS in the overall population and the ESR1 mutation subgroup – Plans for […]

The post Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer appeared first on ThaiPR.NET.

]]>